As diagnostic innovation continues to accelerate, one factor increasingly determines whether patients ultimately benefit from new technologies: coverage.
For clinical laboratories, diagnostic manufacturers, and healthcare providers, Medicare local coverage determinations (LCDs) often serve as the gateway to patient access. Yet many stakeholders have expressed concerns regarding the transparency, consistency, and timeliness of the Medicare LCD process, particularly as emerging technologies become more complex and evidence requirements continue to evolve.
Recognizing these concerns, US Representatives Neal Dunn (R-FL), Nanette Barragán (D-CA), and Claudia Tenney (R-NY) introduced the Timely Access to Coverage Decisions Act of 2026 (H.R.8500). The legislation seeks to reform key aspects of the Medicare LCD process by increasing transparency, establishing accountability measures, and creating more structured timelines for coverage policy development and reconsideration.
As of June 2026, the bill has been introduced and referred to the House of Representatives’ Committees on Ways and Means and Energy and Commerce for further consideration.
While the legislation remains in the early stages of the legislative process, it signals growing Congressional interest in how Medicare coverage policies are developed and how those policies impact patient access to care.
Why Medicare LCDs matter
Coverage policy has become one of the most important determinants of whether innovative diagnostics reach patients.
Whether the technology involves molecular diagnostics, genomic profiling, minimal residual disease (MRD) testing, proteomics, artificial intelligence-enabled diagnostics, or other advanced laboratory services, coverage often becomes the critical bridge between innovation and clinical adoption.
Across the diagnostic industry, stakeholders have raised concerns regarding:
- Lengthy LCD development timelines
- Delays in LCD reconsideration requests
- Limited transparency regarding evidence evaluation
- Variability in stakeholder engagement
- Challenges understanding how coverage decisions are ultimately reached
- Significant changes between draft and final LCDs
These concerns are not theoretical. They affect how quickly patients gain access to emerging technologies and how laboratories make investment decisions related to clinical evidence development, commercialization, and reimbursement strategy.
Key provisions of H.R.8500
The proposed legislation introduces several reforms designed to improve the Medicare LCD process. They are outlined below:
Defined timelines for LCD requests and reconsiderations
One of the most notable provisions would establish clearer timelines for reviewing LCD requests and reconsideration requests.
Today, clinical labs often experience uncertainty regarding when a request will be reviewed or whether additional action is required. Establishing formal timelines could provide greater predictability and reduce delays associated with coverage policy development.
For laboratories seeking Medicare coverage for innovative diagnostics, greater certainty regarding timelines could improve strategic planning and accelerate access to medically necessary testing.
Increased transparency
The bill would require public meetings related to new and revised LCDs to be open to the public, recorded, and posted on Medicare Administrative Contractor websites.
This provision could provide greater visibility into how evidence is reviewed and how coverage decisions are developed.
For laboratories, increased transparency may improve understanding of evidentiary expectations while creating opportunities for more informed stakeholder participation.
Agency review of reconsideration decisions
The legislation would establish a process for agency review of reconsidered Medicare LCD decisions.
This provision would introduce an additional layer of accountability by allowing review of whether evidence supporting a coverage decision was appropriately evaluated and whether coverage regulations were properly applied.
For labs that have historically faced limited options when disagreements arise regarding LCD decisions, this may represent one of the most significant reforms proposed within the legislation.
Assurance that draft and final LCDs match
The bill also would require finalized LCDs to be natural progressions of their draft versions.
If substantial changes are made between the draft and final policy, the LCD would need to be reissued as a draft and reopened for public comment.
This provision seeks to ensure stakeholders have a meaningful opportunity to review and respond to significant policy changes before implementation.
What the bill could mean for laboratories
If enacted, the Timely Access to Coverage Decisions Act could offer several potential benefits for laboratories and diagnostic innovators:
Improved predictability
Coverage development often requires significant investments in clinical studies, evidence generation, health economics research, and market access planning.
More predictable LCD timelines could help laboratories better align evidence development strategies with reimbursement planning and commercialization efforts.
Greater transparency into coverage development
Understanding how evidence is evaluated is critical for laboratories developing innovative diagnostics.
Publicly available meetings and recorded discussions could provide valuable insight into evidentiary expectations and policy considerations, potentially improving future submissions and stakeholder engagement.
Enhanced stakeholder participation
The legislation would reinforce the importance of stakeholder input throughout the LCD development process.
Laboratories, clinicians, professional societies, patient advocacy organizations, and industry groups may have greater opportunities to provide meaningful feedback before policies become final.
Increased accountability
The establishment of agency review mechanisms would introduce additional safeguards designed to ensure coverage decisions are transparent, evidence-based, and procedurally consistent.
Why the diagnostic industry is paying attention
The timing of this legislation is notable. Across the laboratory industry, conversations continue regarding LCD development timelines, reconsideration requests, evolving evidence standards, and the growing volume of innovative technologies seeking Medicare coverage.
Topics frequently discussed by stakeholders include:
- Molecular diagnostic coverage pathways
- MRD testing
- Proteomic testing and emerging biomarkers
- AI-enabled diagnostics
- LCD reconsideration processes
- Coverage policy backlog concerns
- Opportunities for more efficient policy updates when evidence evolves
While H.R.8500 would not alter Medicare’s underlying “reasonable and necessary” coverage standard, it seeks to modernize the process used to evaluate and implement coverage decisions.
For many in the diagnostics industry, the question is no longer whether Medicare should maintain rigorous evidence standards. Rather, the discussion has shifted toward ensuring that coverage policies are developed through a process that is transparent, timely, predictable, and responsive to stakeholder input.
What happens next with the proposal?
Like many pieces of legislation, H.R.8500 faces a lengthy legislative pathway before becoming law.
The bill must advance through committee review, potential amendments, House consideration, Senate review, and ultimately receive presidential approval before implementation. Whether the legislation advances in its current form remains uncertain.
However, its introduction reflects growing recognition that the Medicare LCD process plays a critical role in determining patient access to innovative diagnostic technologies.
Even if the bill evolves significantly during the legislative process, it highlights concerns that many laboratories, clinicians, and patient advocates have raised for years.
Final thoughts on the Timely Access to Coverage Decisions Act
The Timely Access to Coverage Decisions Act is not simply about administrative process reform. At its core, the legislation addresses a broader healthcare policy challenge: ensuring that Medicare coverage development keeps pace with scientific innovation while maintaining appropriate evidentiary standards.
For laboratories and diagnostic innovators, transparency, predictability, and engagement are not merely procedural issues; they directly influence patient access to care.
As policymakers continue to evaluate reforms to the Medicare LCD process, the diagnostic industry should remain engaged in the discussion. The outcome may help shape how future innovations move from scientific breakthrough to clinical practice and, ultimately, to the patients who stand to benefit most.